Roshanak Monzavi, MD
Dr. Monzavi is an associate professor of clinical pediatrics at the Center for Endocrinology, Diabetes, and Metabolism at Children’s hospital Los Angeles (CHLA). She completed her residency training at University of California, Irvine in 2001, and her fellowship training at CHLA in 2004. She joined the division as faculty member in November 2005. Her main clinical interests are in care of patient with Type 1 diabetes and general endocrine disorders. She sees patients at CHLA as well as CHLA's Encino Care Center.
Dr. Monzavi is the director of Pediatric Endocrinology Fellowship Program, and recent recipient of the Gustavus and Louise Pfeiffer Research Foundation award to the fellowship program. She is involved in many educational activities involving, fellows, residents, and medical students.
Dr. Monzavi’s main research interests are clinical care and immunomodulatory therapies for Type 1 Diabetes. She has been the site Principal Investigator (PI) for the TrialNet consortium since 2009, and site PI for T1D Exchanges consortium since 2016. She has co-authored multiple research papers involving multi-center trials lead by these consortia. For current CHLA studies conducted by Dr. Monzavi through TrialNet and T1D Exchange consortia, please click here.
Type 1 Diabetes
General Endocrinology
Education
University of California, Irvine
University of California, Irvine
University of California, Irvine
Children's Hospital Los Angeles
Accomplishments
Pediatric Endocrinology, American Board of Pediatrics
Pediatric Endocrine Society
American Diabetes Association
Publications
Shih EM, Mittelman S, Pitukcheewanont P, Azen CG, Monzavi R**. Effects of vitamin D repletion on glycemic control and inflammatory cytokines in adolescents with type 1 diabetes. Pediatr Diabetes. 17(1):36-43, 2016.
Rigby MR, Harris KM, Pinckney A, DiMeglio LA, Rendell MS, Felner EI, Dostou JM, Gitelman SE, Griffin KJ, Tsalikian E, Gottlieb PA, Greenbaum CJ, Sherry NA, Moore WV, Monzavi R, Willi SM, Raskin P, Keyes-Elstein L, Long SA, Kanaparthi S, Lim N, Phippard D, Soppe CL, Fitzgibbon ML, McNamara J, Nepom GT, Ehlers MR. Alefacept provides sustained clinical and immunological effects in new-onset type 1 diabetes patients. J Clin Invest. 125(8):3285-96, 2015.
Orban T, Bundy B, Becker DJ, Dimeglio LA, Gitelman SE, Goland R, Gottlieb PA, Greenbaum CJ, Marks JB, Monzavi R, Moran A, Peakman M, Raskin P, Russell WE, Schatz D, Wherrett DK, Wilson DM, Krischer JP, Skyler JS; The Type 1 Diabetes TrialNet Abatacept Study Group. Co-Stimulation Modulation with Abatacept in Patients with Recent-Onset Type 1 Diabetes: Follow-Up One Year After Cessation of Treatment. Diabetes Care. 37(4):1069-75, 2014.
Rigby MR, DiMeglio LA, Rendell MS, Felner EI, Dostou JM, Gielman SE, Patel CM, Griffin KJ, Tsalikian E, Gottlieb PA, Greenbaum CJ, Sherry NA, Moore WV, Monzavi R, Willi SM, Raskin P, Moran A, Russell W, Pinckney A, Keyes-Elstein L, Howell M, Aggarwal S, Lim N, Phippard D, Nepom G, McNamara J, Ehlers MR, the TIDAL Study Team. Targeting of memory T cells with alefacept in new-onset type 1 diabetes (T1DAL study): 12 month results of a randomised, double-blind, placebo-controlled phase 2 trial. Lancet Diabetes Endocrinol. 1(4):284-94, 2013.
Wherrett DK, Bundy B, Becker DJ, DiMeglio LA, Gitelman SE, Goland R, Gottlieb PA, Greenbaum CJ, Herold KC, Marks JB, Monzavi R, Moran A, Orban T, Palmer JP, Raskin P, Rodriguez H, Schatz D, Wilson DM, Krischer JP, Skyler JS; Type 1 Diabetes TrialNet GAD Study Group. Antigen-based therapy with glutamic acid decarboxylase (GAD) vaccine in patients with recent-onset type 1 diabetes: a randomised double-blind trial. Lancet. 378(9788):319-27, 2011.
Research
Dr. Monzavi’s main research interests are clinical care and immunomodulatory therapies for Type 1 Diabetes. She has been the site Principal Investigator (PI) for the TrialNet consortium since 2009, and site PI for T1D Exchanges consortium since 2016. She has co-authored multiple research papers involving multi-center trials lead by these consortia.
For current CHLA studies conducted by Dr. Monzavi through TrialNet and T1D Exchange consortia, please click here.
Research Studies
This study aims to identify family members of people with type 1 diabetes that may be at risk for developing type 1 diabetes, and to monitor the metabolic and immunologic status of at-risk individuals. Eligible individuals will be offered enrollment in type 1 diabetes prevention studies.
Abatacept is given as an investigational study drug to relatives of someone with type 1 diabetes who have positive diabetes antibodies in an attempt to prevent or delay the onset of type 1 diabetes.
To evaluate how the Medtronic 670G closed loop system impacts clinical and patient-reported outcomes in individuals with type 1 diabetes.
Hydroxychloroquine is given as an investigational drug to relatives of someone with type 1 diabetes who have positive diabetes antibodies in an attempt to prevent or delay the onset of type 1 diabetes.
To demonstrate that an ultra-fast-acting formulation of insulin lispro is non-inferior to Humalog on measures of glycemic control when administered 0 to 2 minutes before eating in combination with basal insulin.